Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Cardiff Oncology (TROV) News Today

Cardiff Oncology logo

TROV Latest News

Cardiff Oncology announces second patent for onvansertib combination
William Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)
Cardiff Oncology Reports Positive Q3 2024 Results and Clinical Progress
Cardiff Oncology publishes onvansertib combination data in journal
Craig-Hallum Sticks to Its Buy Rating for Cardiff Oncology (CRDF)
H.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)
Cardiff Oncology (NASDAQ: CRDF)
Cardiff Oncology
Cardiff Oncology: Staying The Course
Cardiff Oncology, Inc. (CRDF)
CRDF Cardiff Oncology, Inc.
Cardiff Oncology: Down But Not Out
Get Cardiff Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TROV Media Mentions By Week

TROV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TROV
News Sentiment

0.00

1.12

Average
Medical
News Sentiment

TROV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TROV Articles
This Week

0

0

TROV Articles
Average Week

Get the Latest News and Ratings for TROV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cardiff Oncology and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:TROV) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners